We are pleased to advise that deep linking capability, enabling users to directly download individual mobile toolkits, has now been released on the RDS mobile app. When you install the update, you will see that each toolkit has a small QR code icon the header area beside the search icon – see screenshot below. Clicking on this icon will open up a window with a full-size QR code and the alternative of a short URL for sharing with users. Instructions are provided.
You may need to actively install the update to install RDS app version 4.7.1 to see this improvement. Installing this update is also strongly recommended to get the full benefits of the new contingency arrangements – specifically, that if the RDS website should fail, you will still be able to download new mobile app toolkits.
To check your current RDS version, click on the three dots bottom right of the RDS app screen. This takes you to a “More” page where you will see the version number. To install latest updates:
On iPhones – go to the Apple store, click on your profile icon top right, scroll down to see the apps waiting to be updated and update the RDS app.
On Android phones – these can vary, but try going to the Google Play store, click on your profile icon top right, click on “Manage apps and device”, select and update the RDS app.
Please get in touch with ann.wales3@nhs.scot with any questions.
The following medicines are currently non-formulary within NHS GGC Mental Health Services (MHS) and are subject to mental health non-formulary (MHS-NF) requests:
Peer Approved Clinical System tier 2 (PACS2) is the process that has replaced Individualised Patient Treatment Requests (IPTRs) in most situations.
Within MHS, the only medicine that is currently subject to the PACS2 process (on cost grounds and non-SMC status) is:
Guidance for use of olanzapine embonate long acting injection (Zypadhera) in GGC is available here.
Medicines that do not have a marketing authorisation (or product licence) in the UK are subject to unlicensed medicine (ULM) requests and require completion of a ULM form. These are (not exhaustive):
A number of blanket unlicensed protocols exist within MHS to allow use of some ULMs in certain clinical situations without submitting a full ULM form. These are:
Off-label use of medicines occurs when medication is used outside the terms of its marketing authorisation. Where the off-label use is supported by evidence-based texts, the use is generally considered low risk and a ULM form will not be required. Where the off-label use is higher risk, a ULM form may be required.
Please contact the Mental Health Prescribing Management Group for further advice.(prescribingmanagementgroup.mentalhealth@ggc.scot.nhs.uk)
Following approval of medicines subject to NF, PACS2 or ULM processes, PMG-MH will retain a copy of the form for audit purposes and may request feedback after a period of time in order to evaluate local clinical experience.
MyPsych App